0001209191-18-010129.txt : 20180214 0001209191-18-010129.hdr.sgml : 20180214 20180214181613 ACCESSION NUMBER: 0001209191-18-010129 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180212 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 18614995 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-12 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2018-02-12 4 S 0 875 150.78 D 61650 D Common Stock 2018-02-12 4 S 0 800 152.27 D 60850 D Common Stock 2018-02-12 4 S 0 3879 153.07 D 56971 D Common Stock 2018-02-12 4 S 0 1270 153.80 D 55701 D Common Stock 140 I 401(k) Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $150.78 (range $150.42 to $151.20). Open market sales reported on this line occurred at a weighted average price of $152.27 (range $151.67 to $152.62). Open market sales reported on this line occurred at a weighted average price of $153.07 (range $152.67 to $153.66). Open market sales reported on this line occurred at a weighted average price of $153.80 (range $153.67 to $153.99). /s/ Omar White, Attorney-in-Fact 2018-02-14